RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1016%2Fj.bcmd.2023.102724

https://w3id.org/ripe/ripe-kg/work/10.1016%2Fj.bcmd.2023.102724
SubjectPredicateObject
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP prism:doi 10.1016/j.bcmd.2023.102724
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP dcterms:title Daratumumab as a novel treatment option in refractory ITP
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP rdf:type node1
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP rdf:type rdfs:Resource
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP rdf:type owl:Thing
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP rdf:type prov:Entity
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP rdf:type ripe:WorkWork
ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP owl:sameAs https://semopenalex.org/work/W4315853269
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.bcmd.2023.102724Daratumumab as a novel treatment option in refractory ITP